Abstract 2501
Background
MET addicted tumors are known to show very short response to single MET inhibition. In MET addicted cells, MET inhibition leads to activation of proviral integration site for Moloney murine leukemia virus-1 (PIM1). PIM1 and SRC can regulate the expression of receptor tyrosine kinases (RTKs), potentially being responsible of resistance to MET inhibition. We previously showed that the dual inhibition of MET and PIM1 with class I MET inhibitors and the pan-PIM inhibitor AZD1208, as well as MET and SRC (with dasatinib), is synergistic in MET addicted cell lines.
Methods
We evaluated the activity of class I and class II MET inhibitors, MET/SRC/CSF1R inhibitor TPX-02226 and pan-PIM inhibitors AZD1208 and PIM447 in four MET addicted cell lines: 2 MET amplified lung cancer cell lines (EBC1 and H1993), 1 MET exon 14 mutant cell line (Hs746T) and 1 MET exon 7-8 splicing variant cell line (E98). We assessed the effect of the dual inhibition of MET and PIM, and the triple inhibition of MET, SRC and PIM in cell viability by combining the TPX-02226 with the pan-PIM inhibitors.
Results
All cell lines were sensitive to class I-II MET inhibitors (IC50s in nM range) except for cabozantinib in H1993. Only the MET amplified cell lines were sensitive to TPX-02226. All cell lines were resistant to PIM inhibition. The combination of class I MET inhibitors with PIM447 showed stronger synergism in the MET amplified cell lines, compared to the combination with AZD1208. Class I-II MET inhibitors and PIM inhibitor combination showed only additive effect in exon 7-8 cell line E98, while the combination of TPX-02226 and PIM447 was strongly synergistic.
Conclusions
We identified potential role of PIM inhibition in MET amplified tumors. Even though single agent TPX-02226, AZD1208 or PIM447 showed no activity and dual MET/PIM inhibition showed only additive effect, the triple inhibition of MET, SRC and PIM was strongly effective in MET exon 7-8 splicing variant, suggesting a crucial role of SRC-PIM interaction in this still not well recognized MET addicted tumor. Further investigation on this triple inhibition is ongoing in MET addicted cell lines and role of co-presence of MET and PIM1 and/or SRC alterations in tumor samples.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
IGTP, Germans Trias i Pujol Research Institute, Badalona, Barcelona, Spain.
Funding
Fundació Obra Social “La Caixa”.
Disclosure
J.J. Cui: Leadership role, Officer / Board of Directors: TP Therapeutics. N. Karachaliou: Officer / Board of Directors: Merck KgaA. All other authors have declared no conflicts of interest.
Resources from the same session
2344 - Lung Cancer in Europe: strengthening policy responses to address unmet needs
Presenter: Mary Bussell
Session: Poster Display session 3
Resources:
Abstract
1359 - Curative treatment timelines for breast, colorectal, lung and prostate cancer: Implications for medical leave coverage
Presenter: Selina Wong
Session: Poster Display session 3
Resources:
Abstract
4433 - Acute Diagnostic Oncology Clinic: A Unique Primary Care-Oncology Service
Presenter: Abhijit Gill
Session: Poster Display session 3
Resources:
Abstract
3506 - THE NEW MUTATIONAL MODEL IN ONCOLOGY. What changes in welfare, clinical practice, research, and regulatory procedures
Presenter: Nicola Normanno
Session: Poster Display session 3
Resources:
Abstract
3350 - Selection of a set of quality indicators (QI) for oncological clinical pathway
Presenter: Aude Fourcade
Session: Poster Display session 3
Resources:
Abstract
4400 - Sustainable drug prices at market launch: policy proposals and their empirical evidence
Presenter: Nora Fanzen
Session: Poster Display session 3
Resources:
Abstract
4118 - Impact of financial considerations on French physicians’ prescription choices for advanced non-small cell lung cancer (NSCLC)
Presenter: Nathalie Olympios
Session: Poster Display session 3
Resources:
Abstract
1340 - The direct medical cost of breast cancer in a Belgian hospital
Presenter: Hannan Lemhouer
Session: Poster Display session 3
Resources:
Abstract
1863 - Does the healthcare system approaches cancer patients for using private services during diagnostic process?
Presenter: Karolina Osowiecka
Session: Poster Display session 3
Resources:
Abstract
2637 - Measuring financial toxicity of cancer in the Italian health care system: initial results of the patient reported outcome for Fighting Financial Toxicity of cancer project (proFFiT).
Presenter: Silvia Riva
Session: Poster Display session 3
Resources:
Abstract